National Cancer Screening Register Amendment Act 2024

Overview

The National Cancer Screening Register Amendment Act 2024 was enacted to amend the National Cancer Screening Register Act 2016, extending the scope of the Register to include information relating to lung cancer screening. The Act was introduced to address a gap in the existing legislation that did not cover lung cancer, a significant health concern in Australia. Enacted by the Parliament of Australia, the primary policy objective of this amendment is to improve early detection and management of lung cancer, thereby enhancing patient outcomes. The amendment adds lung cancer to the definition of designated cancer and authorises the inclusion of relevant screening information in the National Cancer Screening Register. The National Cancer Screening Register Amendment Act 2024 commenced on 31 May 2024, the day after receiving Royal Assent. The Act amends the National Cancer Screening Register Act 2016 by inserting a new definition for designated cancer to include lung cancer and by authorising the Register to include information related to lung cancer screening. This legislative change aims to support a more comprehensive approach to cancer screening and management in Australia.

Scope and Application

The National Cancer Screening Register Amendment Act 2024 amends the National Cancer Screening Register Act 2016 to introduce lung cancer into the scope of the register, thereby extending its application to include individuals undergoing screening for this disease. The Act applies to individuals who are subject to screening for lung cancer, as well as to entities and healthcare professionals involved in the administration and management of the screening process. The geographic reach of this Act is national, applying across the Commonwealth of Australia. The Act does not specify any exclusions, exemptions, or thresholds in its primary text, though it is likely that the Act may be further defined or restricted through subordinate instruments that are yet to be enacted. The amendments introduced by this Act are set to commence on 31 May 2024, the day after the Act receives Royal Assent.

Key Provisions

The National Cancer Screening Register Amendment Act 2024 introduces amendments to the National Cancer Screening Register Act 2016, specifically expanding the scope of the register to include information related to lung cancer screening. According to section 1 of the Schedule, the definition of "designated cancer" in section 4 of the 2016 Act is expanded to include lung cancer. Furthermore, section 10 of the 2016 Act is amended to allow the register to include information about individuals in connection with lung cancer screening, as per the new subsection (3) inserted at the end of section 10. Under the amended Act, the obligations of the entities governed by the National Cancer Screening Register Act 2016 now include the responsibility to collect, maintain, and update information related to lung cancer screening. This means that healthcare providers and entities involved in cancer screening must ensure that the register contains accurate and up-to-date information on lung cancer screening activities. They are also required to adhere to the privacy and data protection standards outlined in the 2016 Act to safeguard the personal information of individuals included in the register. Failure to comply with the provisions of the amended Act may result in both civil and criminal consequences. Specifically, breaches of the Act may lead to fines and other penalties. For instance, section 12 of the 2016 Act, which remains applicable to the amended provisions, imposes penalties for unauthorised use or disclosure of personal information. The maximum penalty for individuals is $216,000 or three years imprisonment, or both, while the maximum penalty for bodies corporate is $1,080,000. These penalties underscore the importance of adhering to the legislative requirements to ensure the integrity and security of the cancer screening data.